Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Share-based Compensation (2016 - 2025)

Seres Therapeutics' Share-based Compensation history spans 11 years, with the latest figure at $2.5 million for Q3 2025.

  • For Q3 2025, Share-based Compensation fell 52.11% year-over-year to $2.5 million; the TTM value through Sep 2025 reached $11.4 million, down 48.83%, while the annual FY2024 figure was $21.0 million, 38.5% down from the prior year.
  • Share-based Compensation for Q3 2025 was $2.5 million at Seres Therapeutics, up from $2.3 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $13.5 million in Q2 2023 and bottomed at $2.3 million in Q2 2025.
  • The 5-year median for Share-based Compensation is $5.5 million (2024), against an average of $5.7 million.
  • The largest annual shift saw Share-based Compensation surged 165.31% in 2021 before it tumbled 58.98% in 2024.
  • A 5-year view of Share-based Compensation shows it stood at $5.7 million in 2021, then increased by 28.5% to $7.3 million in 2022, then plummeted by 30.24% to $5.1 million in 2023, then fell by 25.97% to $3.8 million in 2024, then plummeted by 34.08% to $2.5 million in 2025.
  • Per Business Quant, the three most recent readings for MCRB's Share-based Compensation are $2.5 million (Q3 2025), $2.3 million (Q2 2025), and $2.8 million (Q1 2025).